haku: @indexterm bio-technology industry / yhteensä: 101
viite: 3 / 101
| Tekijä: | Hemphill, T.A. |
| Otsikko: | Extraordinary pricing of orphan drugs: is it a socially responsible strategy for the U.S. pharmaceutical industry? |
| Lehti: | Journal of Business Ethics
2010 : JUN III, VOL. 94:2, p. 225-242 |
| Asiasana: | corporate responsibility social responsibility bio-technology industry pharmaceutical industry pricing reputation medical care health consumers USA |
| Vapaa asiasana: | medicines patients access |
| Kieli: | eng |
| Tiivistelmä: | The PRIME Institute of the College of Pharmacy, University of Minnesota, U.S. has released preliminary research findings indicating a trend of extraordinary (henceforth as: exory.) pharmaceutical (herein as: ph-cal/s.) industry pricing of drug products in the United States (U.S.). Such exory. price increases are defined as any price increase that is equal to, or greater than, 100 percent at a single point of time. The PRIME Institute researchers found that drugs exhibiting exory. price increases are categorized as "orphan drugs" or blood-related biologic treatments, being often life-saving or life-sustaining (here as: lf-sts.) for treating the cause or symptoms of diseases affecting fewer than 200,000 people in the U.S. etc. This article deals with two interrelated questions: 1. Are exory. "orphan drug" price increases socially responsible (SR) behaviour? 2. If so, are the ph-cal/s. industry's policies offering "orphan drug" access to American consumers in dire need of available lf-sts. ph-cal/s. considered "SR" behaviour? It is concluded that they are not "SR", unless justified by cost and availability of health care marketplace/patient options. In addition, recommended is a "SR" industry strategic approach to ensure that patients definitely receive, regardless of cost, timely access to lf-sts. "orphan drugs". |
SCIMA